Vistagen Therapeutics (NASDAQ:VTGN) Releases Earnings Results, Beats Expectations By $0.01 EPS

Vistagen Therapeutics (NASDAQ:VTGN) posted its quarterly earnings data on Monday. The company reported ($0.07) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.08) by $0.01, Fidelity Earnings reports.

Shares of Vistagen Therapeutics stock opened at $0.54 on Tuesday. Vistagen Therapeutics has a twelve month low of $0.29 and a twelve month high of $1.49. The business has a 50-day moving average price of $0.48 and a 200-day moving average price of $0.56. The firm has a market cap of $25.92 million, a price-to-earnings ratio of -0.92 and a beta of 0.31.

Several research analysts recently weighed in on the stock. Zacks Investment Research raised shares of Vistagen Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, April 25th. ValuEngine raised Vistagen Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, March 3rd. Finally, Maxim Group reissued a “buy” rating and set a $1.00 target price on shares of Vistagen Therapeutics in a research note on Friday. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Vistagen Therapeutics has an average rating of “Hold” and an average price target of $0.85.

About Vistagen Therapeutics

VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.

See Also: Does the Step Transaction Doctrine Affect a Backdoor Roth IRA?

Earnings History for Vistagen Therapeutics (NASDAQ:VTGN)

Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.